GlassScriptPhysician profile
Milica Antic
NPI 1912494915
$9,749.34
in general payments reported to CMS, 2019-2025
27 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $20.09 · 2022: $2,645 · 2023: $1,263 · 2024: $3,850 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,521 · Food and Beverage: $3,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,521.38 |
| Food and Beverage | $3,346.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $2,436.16 | 2024 | Spiration Valve System, Single Use Suction Valve (Sterile) |
| Inspire Medical Systems, INC. | $1,893.58 | 2022-2024 | Inspire |
| Medical Device Business Services, INC. | $1,271.70 | 2025 | Monarch |
| Glaxosmithkline, LLC. | $817.45 | 2022-2025 | Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $577.22 | 2022-2025 | Airsupra, Tezspire, Fasenra |
| United Therapeutics Corporation | $407.44 | 2022-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $386.07 | 2022-2024 | Xywav |
| Gilead Sciences, INC. | $233.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.41 | 2023-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Grifols USA, LLC | $189.71 | 2023-2025 | Prolastin-C Liquid |
| Inari Medical, INC. | $170.04 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $165.51 | 2024 | Uptravi, Opsumit |
| Pulmonx Corporation | $163.35 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Genzyme Corporation | $130.53 | 2023 | |
| Mallinckrodt Hospital Products INC. | $130.09 | 2024 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $102.41 | 2019 | |
| Csl Behring | $100.01 | 2025 | Hizentra |
| Ethicon INC. | $90.75 | 2025 | Monarch Platform |
| Intuitive Surgical, INC. | $63.30 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.80 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $28.21 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $27.90 | 2025 | Glassia |
| Edwards Lifesciences Corporation | $25.50 | 2024 | Hemosphere |
| Merck Sharp & Dohme LLC | $20.76 | 2022 | |
| Celgene Corporation | $20.09 | 2020 | |
| Bard Peripheral Vascular, INC. | $19.44 | 2023 | |
| Insmed, INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milica Antic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.